23andMe Holding Co. is consumer genetics and research company, which engages to help people access, understand, and benefit from the human genome. The company is headquartered in South San Francisco, California and currently employs 728 full-time employees. The company went IPO on 2020-10-06. The firm's segments include Consumer & Research Services and Therapeutics. The Consumer & Research Services segment comprises its Personal Genome Service (PGS), telehealth business, and research services. Its PGS service provides customers with a suite of genetic reports, including information on customers genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. Its telehealth platform provides patients with access to medical consultation and treatment. Through its research services, it uses its database of genetic and phenotypic information to identify targets for drug development. The Therapeutics segment focuses on the use of genetic insights from its database of genetic and phenotypic information to develop therapies to improve patients lives.